Gefitinib
Back to searchMolecule Structure
Scientific Name
Gefitinib
Description of the Drug
Gefitinib is a tyrosine kinase inhibitor used as first-line therapy to treat non-small cell lung carcinoma (NSCLC) that meets certain genetic mutation criteria.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00317
http://www.drugbank.ca/drugs/DB00317
Brand Name(s)
Iressa
Company Owner(s)
Astrazeneca Uk Ltd, Astrazeneca Pharmaceuticals Lp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Epidermal growth factor receptor erbB1 | SINGLE PROTEIN | INHIBITOR | CHEMBL203 |
Clinical Trial(s)
Unichem Links
| Atlas | gefitinib | ||||
| SureChEMBL | SCHEMBL7866 | ||||
| PharmGKB | PA131301952 | ||||
| Human Metabolome Database | HMDB0014462 | ||||
| DrugBank | DB00317 | ||||
| PubChem: Thomson Pharma | 14833109 | ||||
| PubChem | 123631 | ||||
| Mcule | MCULE-6951584187 | ||||
| LINCS | LSM-1098 | ||||
| Nikkaji | J1.437.124I | ||||
| PDBe | IRE | ||||
| BindingDB | 5447 | ||||
| EPA CompTox Dashboard | DTXSID8041034 | ||||
| DrugCentral | 1282 | ||||
| Brenda | 57709 | 229468 | 17786 | 21851 | 229469 |
| ChemicalBook | CB8120056 | ||||
| Guide to Pharmacology | 4941 | ||||
| rxnorm | GEFITINIB | IRESSA | |||
| PubChem: Drugs of the Future | 12015033 | ||||
| ChEBI | 49668 | ||||
| ZINC | ZINC000019632614 |
